Amgen vs Arrowhead Pharmaceuticals
Amgen (AMGN) and Arrowhead Pharmaceuticals (ARWR) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $236B
- Last close
- $435.64
- 12 months
- +29.6%
- Market value
- $5.85B
- Last close
- $41.37
- 12 months
- +8.6%
At a glance
- By market value, Amgen ($235.6B) is about 40 times Arrowhead Pharmaceuticals ($5.8B).
- Over the last 12 months Amgen's share price moved +29.6% and Arrowhead Pharmaceuticals's +8.6%; against the S&P 500 that is +23.9 points and +2.9 points.
- In their last fiscal years Amgen kept 21.0% of revenue as net income and Arrowhead Pharmaceuticals -160.6%.
- In the last 90 days insiders reported 0 open-market purchases at Amgen and 0 at Arrowhead Pharmaceuticals; members of Congress disclosed 6 trades in Amgen and 0 in Arrowhead Pharmaceuticals.
- Next results: Amgen Feb 1, 2027, Arrowhead Pharmaceuticals Feb 3, 2027.
Share prices on one chart
Amgen and Arrowhead Pharmaceuticals, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Amgen AMGNNASDAQ · Biotechnology | Arrowhead Pharmaceuticals ARWRNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $236B | $5.85B |
| Revenue, last fiscal year | $36.8B | $451M |
| Net income, last fiscal year | $7.71B | −$724M |
| Net marginNet income as a share of revenue | 21.0% | -160.6% |
| Free cash flow | $8.1B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Amgen against
Common questions
How is Amgen different from Arrowhead Pharmaceuticals?
Amgen (AMGN) is in Biotechnology on NASDAQ, with $36.8B of revenue in its last fiscal year and a net margin of 21.0%. Arrowhead Pharmaceuticals (ARWR) is in Biotechnology on NASDAQ, with $451M of revenue in its last fiscal year and a net margin of -160.6%. Both are in the same industry, so the gap is mostly one of size and profitability. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Amgen and Arrowhead Pharmaceuticals compare in size?
Amgen has the larger market value: Amgen $236B and Arrowhead Pharmaceuticals $5.85B, at the last close.
Whose share price rose more over the last 12 months, AMGN or ARWR?
Over the last 12 months Amgen moved +29.6% and Arrowhead Pharmaceuticals +8.6%. Past price moves say nothing about the future.
Which has had more insider buying, Amgen or Arrowhead Pharmaceuticals?
Since 2006, Arrowhead Pharmaceuticals insiders reported 26 open-market purchases against 9 for Amgen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade AMGN or ARWR?
In the last 12 months, members of Congress disclosed 17 trades in Amgen (AMGN) and 0 in Arrowhead Pharmaceuticals (ARWR).
When did insiders last buy AMGN and ARWR?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Amgen pageArrowhead Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/amgn-vs-arwr







